Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium; Warfarin
- Indications Stroke
- Focus Biomarker; Therapeutic Use
- Acronyms ROAD HF-AF
- 09 Jan 2019 Planned End Date changed from 31 Jan 2020 to 1 Jan 2020.
- 09 Jan 2019 Planned primary completion date changed from 31 Dec 2019 to 1 Sep 2019.
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.